Expansion Into Canada Will Shape Global Dermatology Success

Published
23 Feb 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
CA$17.90
20.3% undervalued intrinsic discount
14 Aug
CA$14.26
Loading
1Y
-6.7%
7D
-4.6%

Author's Valuation

CA$17.9

20.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 0.83%

Shared on23 Apr 25
Fair value Decreased 0.50%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 3.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 8.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 20%

AnalystConsensusTarget has decreased revenue growth from 28.5% to 19.8% and decreased profit margin from 35.8% to 32.2%.

Shared on19 Mar 25
Fair value Increased 1.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 28%

AnalystConsensusTarget has increased revenue growth from 15.3% to 28.5%, increased profit margin from 29.8% to 35.8% and increased shares outstanding growth rate from 0.0% to 0.1%.